204 related articles for article (PubMed ID: 1702143)
1. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
Rodriguez G
Invest New Drugs; 1994; 12(2):75-92. PubMed ID: 7532163
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trials with fludarabine phosphate.
Von Hoff DD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine phosphate therapy in other lymphoid malignancies.
Kantarjian HM; Redman JR; Keating MJ
Semin Oncol; 1990 Oct; 17(5 Suppl 8):66-70. PubMed ID: 1699285
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary toxicity associated with fludarabine monophosphate.
Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
[TBL] [Abstract][Full Text] [Related]
7. Issues for the future development of fludarabine phosphate.
Cheson BD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):71-8. PubMed ID: 1699286
[TBL] [Abstract][Full Text] [Related]
8. New initiatives with fludarabine monophosphate in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Keating MJ; Kantarjian H; Talpaz M; Redman J; McCredie KB
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):461-6. PubMed ID: 2464794
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid responsive fludarabine pulmonary toxicity.
Stoica GS; Greenberg HE; Rossoff LJ
Am J Clin Oncol; 2002 Aug; 25(4):340-1. PubMed ID: 12151960
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
Binet JL
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):5-7. PubMed ID: 7685518
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Ross SR; McTavish D; Faulds D
Drugs; 1993 May; 45(5):737-59. PubMed ID: 7686467
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
Ogawa Y; Hotta T; Tobinai K; Watanabe T; Sasaki Y; Minami H; Morishima Y; Ogura M; Seriu T
Ann Oncol; 2006 Feb; 17(2):330-3. PubMed ID: 16275653
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
